MEDI - ETF AI Analysis
Top Page
Harbor Health Care ETF (MEDI)
Rating:62Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains over the past month, three months, and year-to-date, showing positive momentum.
Leading Health Care Names at the Top
Top holdings like Eli Lilly, Ascendis Pharma, Gilead, Legend Biotech, and AbbVie have shown strong or steady performance, helping drive the fund’s returns.
Focused Exposure to Health Care
By concentrating on the health care sector, the ETF gives investors targeted access to a key defensive area of the market that can benefit from long-term demand for medical treatments and services.
Negative Factors
High Stock Concentration
A large share of the fund is invested in just a few companies, especially Eli Lilly and Ascendis Pharma, which increases the impact if any of these stocks stumble.
Several Weak or Lagging Holdings
Some notable positions such as Insmed, Boston Scientific, Intuitive Surgical, and Cencora have shown weak or negative performance, which can drag on overall returns if the trend continues.
Single-Sector, U.S.-Only Focus
With almost all assets in U.S. health care stocks, the ETF lacks diversification across sectors and regions, making it more sensitive to downturns in the domestic health care industry.
MEDI vs. SPDR S&P 500 ETF (SPY)
AUM41.87M
RegionGlobal
Expense Ratio0.80%
Beta0.73
IssuerHarbor
Inception DateNov 17, 2022
Dividend Yield0.23%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,689
30 Day Avg. Volume9,105
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
42.29Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering44
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDI Summary
The Harbor Health Care ETF (MEDI) is a fund that focuses on the health care sector rather than tracking a broad market index. It invests mainly in U.S. companies involved in drugs, biotech, medical devices, and health care services. Well-known holdings include Eli Lilly and AbbVie, along with other specialized medical and biotech firms. Someone might invest in MEDI to tap into long-term growth driven by aging populations and ongoing medical innovation, while still spreading money across many health care names. A key risk is that it is heavily concentrated in health care stocks, so its value can rise or fall sharply with changes in that sector.
How much will it cost me?The Harbor Health Care ETF (MEDI) has an expense ratio of 0.8%, meaning you’ll pay $8 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care companies rather than tracking a broad index.
What would affect this ETF?The Harbor Health Care ETF (MEDI) could benefit from increasing global demand for health care services driven by aging populations, technological advancements, and innovation in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact funding for health care initiatives or the profitability of its top holdings like Eli Lilly and AbbVie. Its global exposure also makes it sensitive to international health policies and economic conditions.
MEDI Top 10 Holdings
MEDI is a pure health care play, and its story starts with Eli Lilly, the heavyweight in the portfolio: despite a recent pause, it’s still one of the main engines pulling long-term returns higher. Ascendis Pharma and Rhythm Pharmaceuticals add a high-growth biotech flavor, but their choppier trading can make the ride bumpier. On the steadier side, Gilead and AbbVie help anchor the fund with more mature drug franchises. With all holdings in global health care names, MEDI is concentrated by sector but diversified across big pharma, biotech, and medical innovators.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 20.56% | $8.61M | $1.09T | 50.70% | 72 Outperform | |
| Ascendis Pharma | 13.58% | $5.69M | $15.66B | 39.79% | 46 Neutral | |
| Gilead Sciences | 5.06% | $2.12M | $162.99B | 15.05% | 78 Outperform | |
| Rhythm Pharmaceuticals | 4.21% | $1.76M | $7.25B | 12.40% | 59 Neutral | |
| AbbVie | 3.12% | $1.31M | $454.79B | 28.54% | 66 Neutral | |
| Intuitive Surgical | 2.78% | $1.16M | $124.70B | -26.86% | 78 Outperform | |
| Cencora | 2.71% | $1.13M | $60.75B | 7.97% | 70 Neutral | |
| Revolution Medicines | 2.56% | $1.07M | $40.85B | 411.96% | 52 Neutral | |
| Insmed | 2.55% | $1.07M | $22.00B | -9.28% | 43 Neutral | |
| Merck & Company | 2.42% | $1.01M | $320.56B | 64.21% | 80 Outperform |
MEDI Technical Analysis
Negative
―
Price Trends
32.30
Positive
31.04
Positive
31.10
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MEDI, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 33.51, equal to the 50-day MA of 32.30, and equal to the 200-day MA of 31.10, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MEDI.
MEDI Peer Comparison
Comparison Results
Performance Comparison
MEDI
Harbor Health Care ETF
32.32
5.21
19.22%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents